Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany

BACKGROUND AND OBJECTIVES: Aclidinium bromide was approved in the European Union for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients in 2012 and in a fixed-dose combination with formoterol in 2014. We characterised new users of aclidinium, aclidinium/formoterol and ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivero-Ferrer, Elena, Olesen, Morten, Plana, Estel, Aguado, Jaume, Saigí-Morgui, Núria, Rubino, Annalisa, Daoud, Sami Z., Lei, Alejhandra, Perez-Gutthann, Susana, Schink, Tania, Kristiansen, Nina Sahlertz, Hallas, Jesper, Pottegård, Anton, Rebordosa, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989814/
https://www.ncbi.nlm.nih.gov/pubmed/35290649
http://dx.doi.org/10.1007/s40261-022-01120-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989814/
https://www.ncbi.nlm.nih.gov/pubmed/35290649
http://dx.doi.org/10.1007/s40261-022-01120-2

Ejemplares similares